Abstract

BackgroundScleroderma is a serious chronic autoimmune disease in which a patient’s disease state manifests in several irregularly spaced longitudinal measures of lung, heart, skin, and other organ systems. Threshold crossings of pulmonary and cardiac measures indicate potentially life-threatening key clinical events including interstitial lung disease (ILD), cardiomyopathy, and pulmonary hypertension (PH). The statistical challenge is to accurately and precisely predict these events by using all of the clinical history for the patient at hand and for a reference population of patients.MethodsWe use a Bayesian mixed model approach to simultaneously characterize each individual’s future trajectories for several biomarkers. We estimate this model using a large population of patients from the Johns Hopkins Scleroderma Center Research Registry. The joint probabilities of critical lung and heart events are then calculated as a byproduct of the mixed model.ResultsThe performance of this approach is substantially better than standard, more common alternatives. In order to predict an individual’s risks in a clinical setting, we also develop a cross-validated, sequential prediction (CVSP) algorithm. As additional data are observed during a patient’s visit, the algorithm sequentially produces updated predictions for the future longitudinal trajectories and for ILD, cardiomyopathy, and PH. The updated prediction distributions with little additional computing, for example within an electronic health record (EHR).ConclusionsThis method that generates real-time personalized risk estimates has been implemented within the electronic health record system for clinical testing. To our knowledge, this work represents the first approach to compute personalized risk estimates for multiple scleroderma complications.

Highlights

  • Scleroderma is a serious chronic autoimmune disease in which a patient’s disease state manifests in several irregularly spaced longitudinal measures of lung, heart, skin, and other organ systems

  • Modeling multivariate measures and events Motivated by the scleroderma example, we develop and apply a Bayesian multivariate mixed effects model to estimate the conditional distribution of each patient’s future biomarker trajectories and even risks given her clinical history

  • Data characteristics We use data from 592 patients who have more than one observation for all predicted forced vital capacity (pFVC), Predicted diffusing capacity of carbon monoxide (pDLCO), ejection fraction (EF), and right ventricular systolic pressure (RVSP). 6189 pFVC and 5791 pDLCO, 4297 EF, and 3296 RVSP observations are used

Read more

Summary

Introduction

Scleroderma is a serious chronic autoimmune disease in which a patient’s disease state manifests in several irregularly spaced longitudinal measures of lung, heart, skin, and other organ systems. Mortality is highest due to pulmonary and cardiac complications of the disease; 35% of scleroderma-related death has been attributed to pulmonary fibrosis, 26% to pulmonary arterial hypertension (PAH) and 26% to cardiac causes [6] Such events are commonly observed in scleroderma patients; for example, pulmonary involvement has been reported in up to 25% of patients at the early stage of diagnosis [7]. Left ventricular ejection fraction (EF), right ventricular systolic pressure (RVSP), and percent predicted forced vital capacity (pFVC) are monitored to detect whether there is emerging cardiomyopathy, pulmonary hypertension (PH) and interstitial lung disease (ILD), respectively. For each of these measures, a value above or below clinically established thresholds is a surrogate for these endpoints

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call